Clinical Trial

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lymphoma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-05-09; most recent amendment 2025-09-23.
Status change: Recruiting → Active, Not Recruiting 2025-09-23
Status change: Not Yet Recruiting → Recruiting 2017-05-12
Trial Details
NCT Number NCT03147885
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)
Conditions Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia +7 more
Enrollment 43 participants
Start Date 2017-06-20
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-29